•  
  •  
 

Subject Area

Clinical Pathology

Article Type

Original Study

Abstract

Objectives The objective of this study was to investigate the possible relationship between CYP2B6 G15631T gene polymorphism and chronic myeloid leukemia (CML) risk. Background The cytochrome P450 (CYP) enzymes constitute one of the biggest gene families and play a vital role in the metabolism of endogenous biomolecules, drugs, and xenobiotics. One of the members of this family, CYP2B6, plays a very important role in metabolizing carcinogens and medications. CYP2B6 G15631T gene polymorphism reduces CYP2B6 enzyme activity. Patients and methods Fifty CML patients and 32 matched healthy controls were enrolled in this study. CYP2B6 G15631T polymorphic variant was detected by PCR-restriction fragment length polymorphism. Results The frequencies of GG genotype (wild type) were 60% and 43% in CML and control groups, respectively. The frequencies of polymorphic GT genotype (heterozygous variant) were found to be 32% in CML patients and 37.5% in controls (P = 0.608). The TT genotype (homozygous variant) was 8% in CML cases and 18.8% in the control group (P = 0.147). The frequency of the T allele was 24% in CML patients and 37.5% in healthy individuals (P = 0.064). We did not find any association between CYP2B6 G15631T polymorphic variant and CML risk. Conclusion CYP2B6 G15631T is not a risk factor for CML. Further studies on this polymorphism using large number of cases may provide valuable information.

Download

Share

COinS